Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 05, 2026
Why Is Space Exploration Technologies Corp. (SPCX) Stock Down -10.21% Today?

Why Is Space Exploration Technologies Corp. (SPCX) Stock Down -10.21% Today?

Key Takeaways

  • SPCX shares tumbled 10.21% to $112.54, wiping out all of the prior session's 9.43% rally and then some.
  • The selloff was driven by SpaceX's first-ever quarterly earnings report, which revealed AI-related capital expenditures of $18.4 billion — far above the roughly $13.2 billion analysts had forecast.
  • Revenue surged 92% year-over-year to $7.81 billion and the net loss narrowed sharply, but investors focused squarely on the spending trajectory.
  • The lockup expiration on August 6, which will release a large tranche of insider shares, added a secondary layer of selling pressure.
  • Broader tech sentiment around AI infrastructure spending has soured in recent weeks, amplifying the negative reaction.
  • Traders are now watching whether the stock can hold above its IPO price of $135 — a level already breached — and how the lockup unlock will affect liquidity.

Opening Summary

Space Exploration Technologies Corp. — better known as SpaceX — saw its stock SPCX plunge 10.21% on Wednesday, dropping to $112.54 from a prior close of $125.33. The selloff came after the company reported its first quarterly results as a public entity. Despite posting revenue of $7.81 billion that handily beat the $6.93 billion consensus and narrowing its net loss to $541 million from $1 billion a year ago, investors zeroed in on one number: $18.4 billion in capital expenditures for the quarter, with $15.8 billion directed at AI infrastructure alone. The market's verdict was swift and unforgiving, reversing a 9.43% regular-session gain from Tuesday and sending shares deep into negative territory.

Earnings Beat Overshadowed by AI Spending Surge

SpaceX's Q2 2026 report was, by most conventional measures, a strong debut. Revenue grew 92% year-over-year to $7.81 billion. The net loss narrowed to $541 million, or $0.09 per share, significantly better than the $0.26 loss analysts had projected. Adjusted EBITDA nearly tripled to $3.5 billion. All three business segments — Space, Connectivity, and AI — posted revenue above consensus estimates.

Yet none of that mattered once investors digested the capital expenditure line. The company spent $18.37 billion in Q2, more than double the prior quarter and roughly $5 billion above the Street's expectation of $13.22 billion. Of that, $15.83 billion flowed into AI compute infrastructure — a figure that dwarfed the $7.7 billion spent in Q1 and the $749 million spent a year earlier. For context, that single-quarter AI spend exceeded what most large-cap tech firms allocate to AI over an entire year.

CFO Bret Johnsen indicated on the earnings call that capex for the next two quarters would remain at similar levels. With total AI capex for the first half of 2026 already reaching $23.55 billion — versus just $3.32 billion in the same period last year — the spending trajectory has alarmed investors still waiting for AI investments across the tech sector to generate clear returns.

Lockup Expiration Adds Supply Overhang

Compounding the earnings-driven selloff is a major structural event: SpaceX's insider lockup period begins to partially expire on August 6, just two trading days after the earnings release. The unlock could release a significant volume of shares held by pre-IPO investors and employees — estimated at roughly three times the current public float — into the market. With the stock already trading well below its $135 IPO price and down roughly 50% from its post-IPO peak near $225, the prospect of additional selling pressure has unsettled an already fragile shareholder base. A larger tranche of roughly 900 million shares becomes eligible for sale after Q3 results later this year, representing a block larger than the entire IPO issuance.

AI Ambitions Meet Market Skepticism

The earnings report also highlighted Elon Musk's aggressive vision for SpaceX's AI business, which includes the xAI integration, the Grok chatbot, the X platform, and an expanding network of terrestrial and orbital data centers. Musk announced an exclusive chip-supply partnership with NVDA, declaring that SpaceX would build future AI services entirely on Nvidia's Vera Rubin GPU architecture. The Starmind AI-1 payload, co-designed with Nvidia, aims to put "datacenter-class compute" into orbit.

Musk projected that SpaceX could reach a $100 billion annualized revenue run rate by December 2026 and pulled forward the $1 trillion revenue target to 2030. But with the AI segment still posting a $1.26 billion operating loss — even as revenue surged 247% to $2.56 billion — the market is increasingly demanding proof that these colossal investments will pay off. JPMorgan analyst Doug Anmuth noted that capex of nearly $200 billion annually in both 2027 and 2028 could further pressure free cash flow, echoing a trend seen across major hyperscalers.

Market Context and Trading Activity

The decline in SPCX fits a broader pattern of investor fatigue with AI-related capital spending. In recent weeks, heavy AI expenditure from META, GOOGL, MSFT, and AMZN has triggered similar post-earnings selloffs. Tuesday saw a broad market rally that lifted SPCX more than 9% during the regular session, but those gains evaporated entirely after the earnings release. Wednesday's trading reflected a market reassessing the risk-reward profile of one of the most expensive and ambitious companies ever to go public. With a market capitalization still around $1.5 trillion, SpaceX remains valued like a mature tech giant despite generating only a fraction of the revenue and no net profit.

What Comes Next for SPCX

The immediate focus for SPCX traders is the August 6 lockup expiration and how much selling pressure materializes from insiders. Beyond that, the company's Starlink business — the only profitable segment, with $1.66 billion in operating income — remains the financial backbone while the AI and Space divisions burn cash. Upcoming Starship test flights, including a potential first-ever tower catch of the upper stage on Flight 14, could provide positive catalysts. However, the third-quarter earnings report later this year, which triggers an even larger share unlock, looms as the next major risk event. Musk's ambitious targets — $100 billion ARR by year-end, $1 trillion in revenue by 2030 — will face continuous scrutiny as quarterly results either validate or undermine the extraordinary valuation.

Trending AI Robots

In volatile market environments like the one currently affecting SPCX, traders often turn to automated strategies for disciplined decision-making. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated standout performance under prevailing market conditions. With hundreds of bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics, only the strongest current performers are featured. Whether you are navigating earnings-driven volatility or sector-wide rotations, exploring these data-driven tools can help sharpen your market approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SPCX

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 40.68B. The market cap for tickers in the group ranges from 4.49 to 1.65T. SPCX holds the highest valuation in this group at 1.65T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 12%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 2%. DFNS experienced the highest price growth at 97%, while VWAV experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was 0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 67
Price Growth Rating: 58
SMR Rating: 79
Profit Risk Rating: 72
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.